Structured evidence table for Potassium Blood Pressure Meta-Analysis, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Potassium Blood Pressure Meta-Analysis | 13 Various factors may contribute to reduced treatment adherence, notably insufficient knowledge, which is a key factor that, alongside considerations such as attitude and satisfaction, affects adherence []. | 1 | Sarmadi Sogand (2026) | The effect of nutrition education interventions on dialysis patients’ outcomes: a systematic review and meta-analysis |
| Potassium Blood Pressure Meta-Analysis | 14 15 16 Failure to comply with dietary guidelines and fluid management in these patients may cause elevated blood pressure, fluid retention, edema, hyperkalemia, hyperphosphatemia, and a heightened risk of cardiovascular disease, potentially leading to recurrent hospitalizations and mortality [,]. | 1 | Sarmadi Sogand (2026) | The effect of nutrition education interventions on dialysis patients’ outcomes: a systematic review and meta-analysis |
| Potassium Blood Pressure Meta-Analysis | Accordingly, dietary programs can be explored for these patients, leveraging multiple educational techniques to prevent complications associated with non-adherence to dietary guidelines or fluid overload []. | 1 | Sarmadi Sogand (2026) | The effect of nutrition education interventions on dialysis patients’ outcomes: a systematic review and meta-analysis |
| Potassium Blood Pressure Meta-Analysis | 1 2 3 4 Chronic kidney disease (CKD) represents a significant global health issue, impacting an estimated 788 million adults in 2023, with a worldwide prevalence rate of 14.2% []. | 1 | Sarmadi Sogand (2026) | The effect of nutrition education interventions on dialysis patients’ outcomes: a systematic review and meta-analysis |
| Potassium Blood Pressure Meta-Analysis | Data from large potential cohorts in the general population and in treated hypertensive patients suggest that hypertension is an independent risk factor for adverse renal outcomes, with a close relationship between the level of blood pressure and the incidence and progression of CKD [,]. | 1 | Bhuiya N M Mahmudul Alam (2026) | Effects of Aliskiren Monotherapy on Chronic Kidney Disease: A Systematic Review and Meta‐Analysis of Blood Pressure and Urinary Protein Excretion Outcomes |
| Potassium Blood Pressure Meta-Analysis | Conversely, CKD is an independent risk factor for the development of hypertension and cardiovascular disease. | 1 | Bhuiya N M Mahmudul Alam (2026) | Effects of Aliskiren Monotherapy on Chronic Kidney Disease: A Systematic Review and Meta‐Analysis of Blood Pressure and Urinary Protein Excretion Outcomes |
| Potassium Blood Pressure Meta-Analysis | However, the ALTITUDE trial gave regulatory warnings that contraindicate combining aliskiren with ACEIs or ARBs for patients with diabetes or those with moderate to severe renal impairment, since duplicate RAS blockade may increase the risk of adverse reactions []. | 1 | Bhuiya N M Mahmudul Alam (2026) | Effects of Aliskiren Monotherapy on Chronic Kidney Disease: A Systematic Review and Meta‐Analysis of Blood Pressure and Urinary Protein Excretion Outcomes |
| Potassium Blood Pressure Meta-Analysis | 1 2 3 1 4 Hypertension is closely interrelated with chronic kidney disease (CKD) as the two worsen each other []. | 1 | Bhuiya N M Mahmudul Alam (2026) | Effects of Aliskiren Monotherapy on Chronic Kidney Disease: A Systematic Review and Meta‐Analysis of Blood Pressure and Urinary Protein Excretion Outcomes |
Source documents